Luis Meza Contreras, MD
Cards
About
Research
Publications
2026
Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma
Govindarajan A, Hansen N, Mercier B, Byron S, Hegde A, Garcia-Mansfield K, Leskoske K, Chawla N, Meza L, Zengin Z, Barragan-Carillo R, Ebrahimi H, Castro D, Dizman N, Hsu J, Chehrazi-Raffle A, Tripathi A, Salgia N, Pal S, Pirrotte P. Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma. Journal For ImmunoTherapy Of Cancer 2026, 14: e012427. PMID: 42086309, PMCID: PMC13150895, DOI: 10.1136/jitc-2025-012427.Peer-Reviewed Original Research
2025
Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma
Jaime-Casas S, Barragan-Carrillo R, Zugman M, Shah K, Ebrahimi H, Mercier B, Castro D, Zang P, LeVee A, Yip W, Li X, Dizman N, Salgia N, Zengin Z, Meza L, Hsu J, Nguyen C, Chehrazi-Raffle A, Pal S, Tripathi A. Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma. Frontiers In Oncology 2025, 15: 1669526. PMID: 41127009, PMCID: PMC12537358, DOI: 10.3389/fonc.2025.1669526.Peer-Reviewed Original Research27Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma
Mercier B, Govindarajan A, Hansen N, Byron S, Hegde A, Leskoske K, Chawla N, Meza L, Zengin Z, Barragan-Carrillo R, Ebrahimi H, Castro D, Jaime-Casas S, Zugman M, Dizman N, Hsu J, Chehrazi-Raffle A, Tripathi A, Salgia N, Pal S, Pirrotte P. 27Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma. The Oncologist 2025, 30: oyaf276.028. PMCID: PMC12509655, DOI: 10.1093/oncolo/oyaf276.028.Peer-Reviewed Original ResearchComprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma
Salgia N, Khan A, Aubrecht W, Twoey G, Chow J, Attwood K, Yu H, Chiello J, Hansen N, Wasik B, Mercier B, Ebrahimi H, Meza L, Maguire O, Mastri M, Whalen C, Minderman H, Pirrotte P, Byron S, Repasky E, Singh P, Bshara W, Wang J, McGray A, Abrams S, Xu B, Eng K, Long M, Pal S, Kauffman E, Muhitch J. Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma. Cancer Cell 2025, 43: 2014-2033.e9. PMID: 40780212, PMCID: PMC12338066, DOI: 10.1016/j.ccell.2025.07.010.Peer-Reviewed Original ResearchComparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma
Jaime-Casas S, Chawla N, Salgia N, Mercier B, Govindarajan A, Li X, Castro D, Ebrahimi H, Barragan-Carrillo R, Zang P, LeVee A, Zugman M, Dizman N, Hsu J, Meza L, Zengin Z, Chehrazi-Raffle A, Dorff T, Pal S, Tripathi A. Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma. JCO Precision Oncology 2025, 9: e2400947. PMID: 40209138, DOI: 10.1200/po-24-00947.Peer-Reviewed Original ResearchEligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion
Mercier B, Govindarajan A, Castro D, Li X, Philip E, Feng M, Prajapati S, Chan E, Lee K, Sehgal I, Patel J, O'Dell A, Chehrazi‐Raffle A, Ebrahimi H, Rock A, Zengin Z, Meza L, Dizman N, Hsu J, Liu S, Dorff T, Pal S, Tripathi A. Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion. Cancer Medicine 2025, 14: e70696. PMID: 40145383, PMCID: PMC11947756, DOI: 10.1002/cam4.70696.Peer-Reviewed Original ResearchImpact of Insurance Status on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
Castro D, Gebrael G, Meza L, Li X, Tripathi N, Tandar C, Sayegh N, Zengin Z, Chehrazi-Raffle A, Govindarajan A, Dizman N, Barragan-Carrillo R, Ebrahimi H, Mercier B, Chawla N, Jaime-Casas S, Salgia N, Zugman M, Hsu J, Philip E, Bergerot C, Agarwal N, Pal S. Impact of Insurance Status on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. JCO Oncology Advances 2025 DOI: 10.1200/oa.24.00015.Peer-Reviewed Original Research
2024
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, Frankel P, Llamas-Quitiquit M, Hsu J, Zengin Z, Alcantara M, Castro D, Mercier B, Chawla N, Chehrazi-Raffle A, Barragan-Carrillo R, Jaime-Casas S, Govindarajan A, Gillece J, Trent J, Lee P, Parks T, Takahashi M, Hayashi A, Kortylewski M, Caporaso J, Lee K, Tripathi A, Pal S. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine 2024, 30: 2576-2585. PMID: 38942995, PMCID: PMC11405272, DOI: 10.1038/s41591-024-03086-4.Peer-Reviewed Original ResearchChemotherapy and Targeted Therapies, Biological Therapies for Renal Cell Carcinoma
Malhotra J, Meza L, Govindarajan A, Pal S. Chemotherapy and Targeted Therapies, Biological Therapies for Renal Cell Carcinoma. 2024, 1-15. DOI: 10.1007/978-3-030-51192-0_98-1.ChaptersPrevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
Ebrahimi H, Battle D, Salgia N, Zengin Z, Dizman N, Meza L, Bergerot C, Barragan-Carrillo R, Hsu J, Castro D, Mercier B, Chawla N, Li X, Tripathi A, Liu S, Chehrazi-Raffle A, Vaishampayan U, Staehler M, Pal S. Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy. Nutrients 2024, 16: 1630. PMID: 38892563, PMCID: PMC11174627, DOI: 10.3390/nu16111630.Peer-Reviewed Original Research